nuvation bio - NUVB
NUVB
Close Chg Chg %
2.59 0.12 4.45%
Closed Market
2.70
+0.12 (4.45%)
Volume: 4.55M
Last Updated:
Nov 21, 2024, 3:59 PM EDT
Company Overview: nuvation bio - NUVB
NUVB Key Data
| Open $2.58 | Day Range 2.55 - 2.74 |
| 52 Week Range 1.22 - 4.16 | Market Cap $870.92M |
| Shares Outstanding 337.57M | Public Float 228.20M |
| Beta 1.36 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.17 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.10M |
NUVB Performance
| 1 Week | 2.66% | ||
| 1 Month | 22.17% | ||
| 3 Months | -6.25% | ||
| 1 Year | 107.69% | ||
| 5 Years | N/A |
NUVB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About nuvation bio - NUVB
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
NUVB At a Glance
Nuvation Bio, Inc.
1500 Broadway
New York, New York 10036
| Phone | 1-332-208-6102 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -75,802,000.00 | |
| Sector | Health Technology | Employees | 51 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
NUVB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.547 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 2.778 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.014 |
NUVB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,486,313.725 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NUVB Liquidity
| Current Ratio | 44.113 |
| Quick Ratio | 44.113 |
| Cash Ratio | 43.739 |
NUVB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -11.719 |
| Return on Equity | -12.03 |
| Return on Total Capital | -12.444 |
| Return on Invested Capital | -11.982 |
NUVB Capital Structure
| Total Debt to Total Equity | 0.662 |
| Total Debt to Total Capital | 0.658 |
| Total Debt to Total Assets | 0.645 |
| Long-Term Debt to Equity | 0.336 |
| Long-Term Debt to Total Capital | 0.334 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Nuvation Bio - NUVB
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| - | 368.00K | 484.00K | 222.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | 368.00K | 484.00K | 222.00K | |
Depreciation
| - | 368.00K | 484.00K | 222.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | +31.52% | -54.13% | - |
Gross Income
| - | (368.00K) | (484.00K) | (222.00K) | |
Gross Income Growth
| - | - | -31.52% | +54.13% | - |
Gross Profit Margin
| - | - | - | - | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 3.06M | 92.95M | 119.25M | 99.60M | |
Research & Development
| - | 69.04M | 87.81M | 71.29M | |
Other SG&A
| 3.06M | 23.91M | 31.43M | 28.31M | |
SGA Growth
| - | +2,936.14% | +28.29% | -16.48% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 15.16M | (4.23M) | (10.19M) | (497.00K) | |
EBIT after Unusual Expense
| (18.23M) | (89.09M) | (109.55M) | (99.33M) | |
Non Operating Income/Expense
| 7.01K | 2.24M | 5.35M | 23.52M | |
Non-Operating Interest Income
| 7.01K | 2.96M | 7.45M | 24.61M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (18.22M) | (86.85M) | (104.20M) | (75.80M) | |
Pretax Income Growth
| - | -376.68% | -19.98% | +27.25% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (18.22M) | (86.85M) | (104.20M) | (75.80M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (18.22M) | (86.85M) | (104.20M) | (75.80M) | |
Net Income Growth
| - | -376.68% | -19.98% | +27.25% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (18.22M) | (86.85M) | (104.20M) | (75.80M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (18.22M) | (86.85M) | (104.20M) | (75.80M) | |
EPS (Basic)
| -0.9872 | -0.4389 | -0.4808 | -0.3463 | |
EPS (Basic) Growth
| - | +55.54% | -9.55% | +27.97% | |
Basic Shares Outstanding
| 18.46M | 197.89M | 216.72M | 218.88M | |
EPS (Diluted)
| -0.9872 | -0.4389 | -0.4808 | -0.3463 | |
EPS (Diluted) Growth
| - | +55.54% | -9.55% | +27.97% | |
Diluted Shares Outstanding
| 18.46M | 197.89M | 216.72M | 218.88M | |
EBITDA
| (3.06M) | (92.95M) | (119.25M) | (99.60M) | |
EBITDA Growth
| - | -2,936.14% | -28.29% | +16.48% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 6.75 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.136 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -2.162 | |
| Last Quarter’s Earnings | -0.15 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.35 | Next Fiscal Year Estimate | -0.612 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 3 | 5 | 5 |
| Mean Estimate | -0.14 | -0.15 | -2.16 | -0.61 |
| High Estimates | -0.10 | -0.13 | -1.98 | -0.52 |
| Low Estimate | -0.17 | -0.16 | -2.27 | -0.68 |
| Coefficient of Variance | -19.17 | -10.41 | -5.70 | -10.68 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Nuvation Bio - NUVB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Nuvation Bio - NUVB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 10, 2024 | Philippe Sauvage Chief Financial Officer | 750,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 26, 2024 | Decheng Capital LLC Director | 1,762,951 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.99 per share | 5,271,223.49 |
| Jun 26, 2024 | Decheng Capital LLC Director | 1,838,362 | Open market or private purchase of non-derivative security Non-derivative transaction at $3 per share | 5,515,086.00 |
| Jun 26, 2024 | Decheng Capital LLC Director | 2,175,236 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.98 per share | 6,482,203.28 |
| Jun 14, 2024 | Kim D. Blickenstaff Director | 172,189 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.9 per share | 499,348.10 |
| May 30, 2024 | Daniel G. Welch Director | 293,203 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.74 per share | 510,173.22 |
| May 30, 2024 | Daniel G. Welch Director | 659,947 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.64 per share | 1,082,313.08 |
| May 30, 2024 | Daniel G. Welch Director | 19,547 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 30, 2024 | Daniel G. Welch Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 12, 2024 | Colleen Sjogren Chief Commercial Officer | 500,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 12, 2024 | Colleen Sjogren Chief Commercial Officer | 250,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 12, 2024 | Jun Yuan Wang CEO, ANHEART THERAPEUTICS LTD.; Director | 388,299 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 12, 2024 | Jun Yuan Wang CEO, ANHEART THERAPEUTICS LTD.; Director | 486,669 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 12, 2024 | Jun Yuan Wang CEO, ANHEART THERAPEUTICS LTD.; Director | 550,758 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 12, 2024 | Jun Yuan Wang CEO, ANHEART THERAPEUTICS LTD.; Director | 1,378,989 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2024 | David C. Hanley CHIEF TECHNICAL OPERATIONS | 500,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2024 | Stacy Markel CHIEF PEOPLE OFFICER | 500,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2024 | Gary Hattersley CHIEF SCIENTIFIC OFFICER | 500,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2024 | Dong Fang Liu CHIEF MEDICAL OFFICER | 500,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 5, 2024 | Kerry A. Wentworth CHIEF REGULATORY OFFICER | 500,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |